Holdaway I M, Wallace E, Westbrooke L, Gamble G
Department of Endocrinology, Auckland Hospital, New Zealand.
Int J Obes Relat Metab Disord. 1995 Oct;19(10):749-51.
The effect of the serotonergic agent dexfenfluramine on weight loss, blood pressure, insulin sensitivity and serum lipid levels was determined in a 3-month randomised, double-blind, placebo controlled parallel design study in 50 obese subjects (body mass index 30-44 kg/m2). When compared with placebo treated patients, the dexfenfluramine group lost more weight (3.8 vs 1.1 kg, P < 0.01), had lower diastolic blood pressure (-5 vs -1.5 mmHg, P < 0.05), and lower cholesterol levels (-0.38 vs + 0.06mmol/l, P < 0.05), and showed improved insulin sensitivity (+ 11% vs + 4%, P < 0.03). Significant effects on blood pressure and insulin sensitivity were apparent after 1 week of treatment during which time weight did not change, suggesting a direct effect of the agent independent of weight loss. Dexfenfluramine thus improves a number of cardiovascular risk factors associated with obesity, with benefits additional to those achieved by weight reduction alone.
在一项针对50名肥胖受试者（体重指数为30 - 44kg/m²）开展的为期3个月的随机、双盲、安慰剂对照平行设计研究中，测定了血清素能药物右芬氟拉明对体重减轻、血压、胰岛素敏感性和血脂水平的影响。与接受安慰剂治疗的患者相比，右芬氟拉明组体重减轻更多（3.8kg对1.1kg，P < 0.01），舒张压更低（-5mmHg对-1.5mmHg，P < 0.05），胆固醇水平更低（-0.38mmol/l对+0.06mmol/l，P < 0.05），并且胰岛素敏感性有所改善（+11%对+4%，P < 0.03）。治疗1周后，对血压和胰岛素敏感性即出现显著影响，而在此期间体重未发生变化，这表明该药物具有独立于体重减轻的直接作用。因此，右芬氟拉明改善了许多与肥胖相关的心血管危险因素，其益处不仅仅是单纯减轻体重所带来的。
